Table 3 Summary of participant characteristics
Reference | Dx | Sample (n) | Age (years, average (SD) | Sex, female (%) | Illness duration | Marker assessed | Sample source | |||
|---|---|---|---|---|---|---|---|---|---|---|
ME/CFS/SEID | HC | ME/CFS/SEID | HC | ME/CFS/SEID | HC | |||||
Armstrong et al. [5] | Canadian Criteria | 34 | 25 | 34.9 (1.8 SE) | 33.0 (1.6 SE) | 100% | 100% | NR | Metabolites | Whole blood and urine |
Billing-Ross et al. [6] | Fukuda Criteria, Canadian Criteria | 193 | 196 | NR | NR | NR | NR | NR | mtDNA | DNA |
Booth et al. [7] | Fukuda Criteria | 138 | 53 | Cohort 1: 45.1 (11.8) Cohort 2: 41.1 (12.1) | 35.9 (13.4) | Cohort 1: 79% Cohort 2: 70% | 76% | NR | ATP | Neutrophils |
Castro-Marrero et al. [8] | Fukuda Criteria | 23 | 15 | 44.1 (3.8) | 43.5 (5.4) | 65.2% | 66.7% | 15.6 (10.8) | CoQ10, ATP, lipid peroxidation, Mitochondrial citrate synthase activity, mTDNA, Expression levels of peroxisome proliferator-activated receptor gamma-coactivator 1-alpha and transcription factor A | PBMCs |
Germain et al. [9] | Fukuda Criteria, IOM 2015 | 17 | 15 | 53.9 (6.2) | 51.9 (6.2) | 100% | 100% | NR | Metabolites | Whole blood |
Light et al. [10] | Fukuda criteria | 39 | 22 | 40–79 | 40–79 | NR | NR | NR | mRNA | Leukocytes |
Maes et al. [11] | Fukuda Criteria | 58 | 22 | 38.5 (13.9) | 45.4 (10.1) | 86.2% | 77.3% | NR | Coenzyme Q10 | Plasma |
Mandarano et al. [12] | Canadian Criteria | 53 | 45 | 50.8 (16.2) | 50.2 (17.5) | 58.5% | 57.8% | 21.7 | Mitochondria | T cells |
Missailidis et al. [22] | Canadian Criteria | 51 | 22 | 26–70 | 21–58 | 86% | 68% | NR | Mitochondria | Lymphoblasts |
Missailidis et al. [23] | Canadian Criteria | 51 | 22 | 26–70 | 21–58 | 86% | 68% | NR | Mitochondria | PBMCs Lymphoblasts |
Naviaux et al. [13] | Canadian Criteria, Fukuda Criteria, IOM 2015 | 45 | 39 | F: 52 (2.5) M: 53 (2.8) | F: 48 (2.8) M: 53 (3.5) | 51.1% | 53.8% | F: 17 (2.3) M: 21 (3.0) | Metabolites | Plasma |
Nguyen et al. [14] | Fukuda Criteria | 17 | 19 | 48.68 (1.06) | 46.48 (1.22) | 82.4% | 68.4% | 8.4 | TRPM3 surface expression | NK cells, B lymphocytes |
Nguyen et al. [15] | Fukuda Criteria, International Consensus Criteria | 6 | 6 | 50.33 (4.95) | 50.00 (5.04) | 83.3% | 83.3% | NR | Mitochondria | NK cells |
Plioplys and Plioplys [16] | Fukuda Criteria | 15 | 15 | 18–58 | 19–58 | 53.3% | 53.3% | 8 months–20 years | Mitochondria | Percutaneous needle muscle biopsies |
Shungu et al. [17] | Fukuda Criteria | 15 | 13 | 32.7 (8.6) | 27.6 (7.4) | 80% | 53.8% | 9.7 (9.1) | Metabolites | Cerebrospinal fluid |
Sweetman et al. [18] | Canadian Criteria | 10 | 10 | 36.4 | 38.8 | 60% | 60% | 12.6 | RNA | PBMCs |
Tomas et al. [19] | Fukuda Criteria | 52 | 35 | 42.8 (13.7) | 36.6 (12.0) | 84.6% | 77.1% | NR | Mitochondria | PBMCs |
Venter et al. [20] | Fukuda Criteria | UK: 89 moderate, 29 severe RSA: 143 moderate | UK: 64 RSA:98 | NR | NR | NR | NR | NR | mtDNA | mtDNA |
Yamano et al. [21] | Fukuda Criteria | Training: 47 Validation: 20 | Training: 46 Validation: 20 | Training: 38.08 (6.57) Validation: 36.15 (8.14) | Training: 38.78 (9.71) Validation: 36.10 (8.35) | Training: 87.2% Validation: 100% | Training: 89.1% Validation: 100% | NR | Metabolites | Plasma |